A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole for the treatment of acute manic or mixed episodes in Asian patients with bipolar I disorder (the AMAZE study).

@article{Kanba2014APD,
  title={A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole for the treatment of acute manic or mixed episodes in Asian patients with bipolar I disorder (the AMAZE study).},
  author={Shigenobu Kanba and Hiroaki Kawasaki and Jun Ishigooka and Kaoru Sakamoto and Toshihiko Kinoshita and Toshihide Kuroki},
  journal={The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry},
  year={2014},
  volume={15 2},
  pages={113-21}
}
OBJECTIVES To investigate the efficacy and safety of aripiprazole in Asian patients with manic or mixed episodes associated with bipolar I disorder. METHODS Subjects were randomised to aripiprazole (24 mg/day; reduced to 12 mg/day if needed for tolerability; n = 128) or placebo (n = 130) for 3 weeks in this multicentre, double-blind study. The primary efficacy measure was mean change from baseline in Young Mania Rating Scale (YMRS) Total score. RESULTS A total of 136 patients (aripiprazole… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 32 references

A comparison of two fi

  • RS El Mallakh, E Vieta, L Rollin, R Marcus, WH Carson, R. McQuade
  • 2010
1 Excerpt

A comparison of two fi xed doses of aripiprazole with placebo in acutely relapsed , hospitalized patients with bipolar disorder I ( manic or mixed ) in subpopulations ( CN 138007 )

  • A Fagiolini, KN Chengappa, I Soreca, J Chang
  • Eur Neuropsychopharmacol
  • 2010

Similar Papers

Loading similar papers…